We really need good treatments for Alzheimer’s. But Biogen’s very expensive (and maybe not very effective) drug Aduhelm is not the treatment we’re looking for. Today we look at the saga of Adulhelm’s approval and its road to acceptance (or lack thereof) in the medical community.
